Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2000 June; 1(2): 37–44.
Published online 2015 February 19. doi:  10.1208/pt010211
PMCID: PMC2784822

Quantitative analysis of thymosin α1 in human serum by LC-MS/MS


1 high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was developed to measure the thymosin alpha 1 (Tα1) concentration in human serum. Tα1 in human serum was determined by solid phase extraction and reverse phase LC-MS/MS. The high-performance liquid chromatography (HPLC) system interfaced with the MS/MS system with a Turbo Ion spray interface. Positive ion detection and multiple reaction monitoring (MRM) mode were used for this human serum quantitation. Eight different concentration standards were used to establish the detection range. Six quality control (QC) and 2 matrix blanks were checked by calibration curves performed on the same day. The lower quantitation limit was 0.5 ng/mL T α1 in human serum. Calibration curves were established between 0.5 to 100 ng/mL by weighted linear regression. The correlation coefficients for different days were 0.9955 or greater. Quantitation of Tα1 by the LC-MS/MS method is fast accurate, and precise.

Keywords: Thymosin α1, LC-MS/MS, solid phase extraction, peptide analysis

Full Text

The Full Text of this article is available as a PDF (102K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology. 1991;14:409–415. doi: 10.1002/hep.1840140302. [PubMed] [Cross Ref]
2. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alphal in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology. 1998;27:1383–1387. doi: 10.1002/hep.510270527. [PubMed] [Cross Ref]
3. Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin alpha 1 versus interferon alpha treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA—positive chronic hepatitis B. Hepatology. 1996;24:774–777. [PubMed]
4. Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alphal and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology. 1998;27:1128–1135. doi: 10.1002/hep.510270430. [PubMed] [Cross Ref]
5. Rasi G, DiVirgilio D, Mutchinick MG, et al. Combination thymosin al and lymphoblastoid interferon treatment in chronic hepatitis C. Gut. 1996;39:670–683. doi: 10.1136/gut.39.5.679. [PMC free article] [PubMed] [Cross Ref]
6. Moscarella S, Buzzelli G, Monti M, et al. Treatment with interferon-alpha and thymosin alpha 1 of naive patients affected by chronic hepatitis C.4th International Meeting on Hepatitis C Virus and Related Viruses. Kyoto, Japan, 1997.
7. Garaci E, Rocchi G, Perroni L. et al. Combined therapy with zidovudine-thymosin alpha 1-alpha interferon in the treatment of HIV-infected patients.Second International Symposium on Combination Therapies, Sicily, Italy, 1992.
8. Garaci E, Milanese G, Vella S, et al. A randomized controlled study for the evaluation of the activity of a triple combination of zidovudine, thymosin alpha 1 and interferon alpha in HIV-infected individuals with CD4 counts between 200 and 500 cells mm3. Antiviral Therapy. 1998;3:103–111.
9. Gravenstein S, Ershler WB, Drumaskin S, Schwab R, Weksler ME. Anti-influenze antibody response: augmentation in elderly “non-responders” by thymosin alpha 1. Gerontologist. 1986;26:150A–150A. doi: 10.1093/geront/26.2.150. [PubMed] [Cross Ref]
10. Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Am Geriatr Soc. 1989;37:1–8. [PubMed]
11. McConnell L, Gravenstein S, Roecker E, Spencer S, Simon G, Erschler W. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1. The Gerentologist. 1989;29:188A–188A.
12. Lopez M, Di Lauro L, Vici P. et al. Biological agents and chemotherapy in the treatment of solid tumors, Third International Symposium on Combination Therapies, Houston, Texas. 1993. Institute for Advanced Studies in Immunology & Aging.
13. Lopez M, Carpano S, Cavaliere R, DiLauro L, Ameglio F, Vitelli G. Biochemotherapy with thymosin alpha 1. interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Annals of Oncology. 1994;5:741–746. [PubMed]
14. Sztein M, Serrate S. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. 1989;11:789–800. doi: 10.1016/0192-0561(89)90133-1. [PubMed] [Cross Ref]
15. Serrate S, Schulof R, Leondaridis L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol. 1987;139:2338–2343. [PubMed]
16. Di Francesco P, Pica F, Gaziano R, Favalli C, Garaci E. In vivo recovery of natural killer cell activity by the association of thymosin a 1 and cytokines during cocaine administation. Medical Science Research. 1994;22:41–42.
17. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol. 1989;11:443–450. doi: 10.1016/0192-0561(89)90172-0. [PubMed] [Cross Ref]
18. Ershler W, Moore A, Socinski M. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol. 1984;4:445–454. doi: 10.1007/BF00916574. [PubMed] [Cross Ref]
19. Effros RB, Casillas A, Walford RL. The effect of thymosin alpha 1 on immunity to influenza in aged mice. New York, New York: Mary Ann Liebert, Inc; 1988. pp. 31–40.
20. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Ageing Dev. 1997;94:85–101. doi: 10.1016/S0047-6374(96)01860-X. [PubMed] [Cross Ref]
21. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Thymosin-alphal stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model [In Process Citation] Int J Immunopharmacol. 1999;21:15–26. doi: 10.1016/S0192-0561(98)00060-5. [PubMed] [Cross Ref]
22. Goldstein A, Low T, Thurman G, et al. Current status of thymosin and other hormones of the thymus gland. Recent Prog Horm Res. 1981;37:369–415. [PubMed]
23. Low TLK, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha 1 and polypeptide beta 1 from calf thymus. J Biol Chem. 1979;254:981–986. [PubMed]
24. Low T, McClure J, Rossio J, Naylor P, Spangelo B, Goldstein A. Isolation of thymosin alpha 1 from thymosin fraction 5 of different species by high performance liquid chromatography. J Chromatogr. 1983;266:533–544. doi: 10.1016/S0021-9673(01)90924-0. [PubMed] [Cross Ref]
25. Low T, Thurman G, Chincarini C, et al. Current status of thymosin research: Evidence for the existence of a family of thymic factors that control T-cell maturation. Ann N Y Acad Sci. 1979;332:33–48. doi: 10.1111/j.1749-6632.1979.tb47095.x. [PubMed] [Cross Ref]
26. Oates K, Erdos M. Biochemical identification of thymosin alpha-1: its phylogenetic distribution and evolutionary implications. Comp Biochem Physiol. 1989;94-B:759–763. [PubMed]
27. Weller FE, Shah U, Cummings GD, Chretien PB, Mutchnick MG. Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults. Thymus. 1992;19:45–52. [PubMed]
28. Sherman K, Jones C, Goldstein A, Naylor P. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol. 1991;4:195–199. doi: 10.1089/vim.1991.4.195. [PubMed] [Cross Ref]
29. Welch R, Mutchnick M, Welter F, Sokol R. Maternal and fetal circulating levels of thymosin alpha 1 during parturition. Am J Reprod Immunol Microbiol. 1987;13:125–127. [PubMed]
30. Welch R, Lee H, Sokol R, Mutchnick M. Amniotic fluid thymosin alpha 1 levels increase during gestation. Am J Reprod Immunol Microbiol. 1988;17:96–97. [PubMed]
31. Rost K, Wierich W, Masayuki F, Tuthill C, Horwitz D, Hermann W. Pharmacokinetics of thymosin alpha 1 after subcutaneous injection of three different formulations in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 1999;37:51–57. [PubMed]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists